| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $1,425,207 ) |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA296618 | Exploiting a Novel DNA Repair Defect in Ewing Sarcoma | 000 | 2 | NIH | 12/5/2025 | $470,964 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U01AI165442 | Identification of Metabolic and Immune Deficits in the Aged Population and Their Restoration to Achieve Youthful Anti-Influenza Vaccine Responsiveness | 000 | 5 | NIH | 11/26/2025 | $1,164,461 |
| | 2026 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R35CA242427 | Reading mitochondrial apoptotic signaling to identify active cancer therapeutics | 000 | 7 | NIH | 11/14/2025 | $0 |
| | 2026 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99CA283154 | Targeting mitochondrial vulnerabilities to drive intrinsic melanoma immunogenicity | 000 | 2 | NIH | 11/19/2025 | $0 |
| | 2026 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | T32CA136432 | Research Training in Pediatric Oncology | 000 | 15 | NIH | 11/21/2025 | -$210,218 |
| | 2026 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01DK124115 | Mitochondria mediated intercellular metabolic coupling in bone marrow regeneration | 000 | 4 | NIH | 11/20/2025 | $0 |
| | 2026 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA248910 | Scaling up tobacco control in India: Comparing smartphone to in-person training for implementing an evidence-based intervention to reduce tobacco use among schoolteachers | 000 | 4 | NIH | 12/9/2025 | $0 |
| | 2026 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA240816 | Characterizing the LINE-1 Retrotransposition-Replication Conflict | 000 | 5 | NIH | 11/25/2025 | $0 |
| | 2026 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | P01AI143565 | Biology and structure of pMHC receptors functioning as mechanosensors in the [alpha][beta] T-cell lineage | 000 | 5 | NIH | 11/17/2025 | $0 |
| | 2026 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA237414 | CDK7 inhibitors as a new strategy to overcome treatment resistance in ER+ metastatic breast cancer | 000 | 5 | NIH | 11/21/2025 | $0 |
| | 2026 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | P01CA229092 | Immune Modulation After Allogeneic HCT | 000 | 5 | NIH | 12/8/2025 | $0 |
| | 2026 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | P50CA168504 | Dana-Farber/Harvard Cancer Center SPORE in Breast Cancer | 000 | 10 | NIH | 11/21/2025 | $0 |
| | 2026 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R21CA262991 | Targeting MUC1-C with an antibody drug conjugate for the therapy of advanced prostate cancer | 000 | 1 | NIH | 11/26/2025 | $0 |
| | 2026 | 2019 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U01CA243688 | The AYA-RISE Intervention: Risk Information and Screening Education for Adolescents and Young Adults with Cancer Predisposition Syndromes | 001 | 1 | NIH | 11/20/2025 | -$389,915 |
| | 2026 | 2019 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U01CA243688 | The AYA-RISE Intervention: Risk Information and Screening Education for Adolescents and Young Adults with Cancer Predisposition Syndromes | 000 | 1 | NIH | 11/20/2025 | $389,915 |
|
| Issue Date FY: 2025 ( Subtotal = $171,860,510 ) (Continued on the next page) |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01DK142741 | Structural Basis of Thermogenic Mitochondrial Respiratory Complexes Assembly | 000 | 1 | NIH | 7/21/2025 | $813,511 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K00CA284254 | Defining Therapeutically Targetable Regulators of Tumor-Intrinsic Immune Suppression in Glioblastoma | 000 | 3 | NIH | 2/13/2025 | $99,216 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U10CA180794 | ECOG-ACRIN Network Group Statistics and Data Management Center | 001 | 11 | NIH | 7/16/2025 | $3,099,295 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U10CA180794 | ECOG-ACRIN Network Group Statistics and Data Management Center | 000 | 11 | NIH | 2/28/2025 | $4,683,890 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U24CA294203 | Enhancement and further development of informatics methods for long-read cancer sequencing | 000 | 2 | NIH | 9/10/2025 | $858,034 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U01CA281840 | Immunotherapeutic targeting of gangliosides in Ewing Sarcoma | 000 | 3 | NIH | 9/4/2025 | $767,167 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F31CA301844 | Unraveling the Mechanisms of Neoantigen Vaccine-Induced Epitope Spreading | 000 | 1 | NIH | 6/27/2025 | $36,538 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F31CA301844 | Unraveling the Mechanisms of Neoantigen Vaccine-Induced Epitope Spreading | 001 | 1 | NIH | 6/27/2025 | $0 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | UG1CA233180 | NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care | 001 | 6 | NIH | 9/9/2025 | $384,756 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | UG1CA233180 | NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care | 000 | 6 | NIH | 3/5/2025 | $664,023 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K00CA253731 | Targeting Oncogenic Drivers in Cancer | 000 | 6 | NIH | 2/14/2025 | $97,605 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08CA283279 | Molecular Dynamics of Glioma Formation and DNA Damage Response by Mutant IDH1 | 000 | 2 | NIH | 3/13/2025 | $299,403 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA279221 | Dissecting Integrated Cellular Programs Promoting Platinum Resistance and Progression in Bladder Cancer | 001 | 2 | NIH | 5/22/2025 | $72,511 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA279221 | Dissecting Integrated Cellular Programs Promoting Platinum Resistance and Progression in Bladder Cancer | 000 | 2 | NIH | 3/4/2025 | $652,606 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA300092 | Mapping the epigenetic dynamics of prostate cancer progression: integrating liquid biopsies and single-cell epigenomics for early detection of lineage plasticity and clinical decision-making | 000 | 1 | NIH | 2/27/2025 | $627,474 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01DK078081 | Metabolic crosstalks in regulation of beta-cell stress response and adaptation | 001 | 13 | NIH | 6/12/2025 | $49,301 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01DK078081 | Metabolic crosstalks in regulation of beta-cell stress response and adaptation | 000 | 13 | NIH | 3/3/2025 | $443,718 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | UG1HL069249 | BMT CTN Core - Dana-Farber Cancer Institute and MGH Consortium | 001 | 25 | NIH | 7/23/2025 | $257,014 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08CA248727 | Investigating Transcriptional Elongation and Nuclear RNA Surveillance in Melanoma | 000 | 6 | NIH | 3/7/2025 | $195,902 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA155010 | Personal tumor neoantigens for immunity against chronic lymphocytic leukemia | 001 | 14 | NIH | 5/22/2025 | $75,920 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA155010 | Personal tumor neoantigens for immunity against chronic lymphocytic leukemia | 000 | 14 | NIH | 2/14/2025 | $683,283 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA270040 | BOLSTER: Strengthening Patient and Caregiver Supports in Advanced Gynecologic and Gastrointestinal Cancers - a Multi-Site Randomized Controlled Trial | 001 | 3 | NIH | 8/1/2025 | $683,515 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08CA252639 | Can a subset of patients with HER2+ metastatic breast cancer be cured? | 000 | 5 | NIH | 3/7/2025 | $258,035 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01DK082889 | Transcriptional control and enhancer recruitment in mouse and human intestinal secretory differentiation | 000 | 13 | NIH | 2/17/2025 | $335,359 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA230503 | Biomarker screening algorithms for the improved early detection of hepatocellular carcinoma | 000 | 7 | NIH | 3/10/2025 | $232,631 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA230503 | Biomarker screening algorithms for the improved early detection of hepatocellular carcinoma | 001 | 7 | NIH | 6/18/2025 | $25,847 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99GM157510 | Revealing Cellular Determinants of LINE-1 Retrotransposition Outcomes | 000 | 1 | NIH | 8/8/2025 | $109,448 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R50CA251956 | Single cell investigation of co-evolution in cancer cells and host cell immune microenvironment | 000 | 6 | NIH | 7/25/2025 | $327,006 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08CA279891 | Epigenetic regulators define a dynamic chromatin landscape in NUP98-rearranged leukemia | 000 | 2 | NIH | 1/27/2025 | $215,179 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R37CA289639 | HEME-Hospice: An Intervention to improve Hospice Use for Patients with Hematologic Malignancies | 000 | 2 | NIH | 6/10/2025 | $643,670 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA293091 | Assessment of germline variants associated with immune-related adverse events following immune checkpoint inhibitors | 000 | 2 | NIH | 9/3/2025 | $668,053 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01AG089237 | Individualizing Approaches to Surveillance Mammography in Older Breast Cancer Survivors | 000 | 2 | NIH | 8/15/2025 | $833,902 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R00CA286805 | Dissecting the Role of Germline Genetics in RAS-Driven Cancers | 000 | 3 | NIH | 8/14/2025 | $248,999 |
|
